{"id":69029,"date":"2026-03-13T12:12:34","date_gmt":"2026-03-13T12:12:34","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=69029"},"modified":"2026-05-21T07:14:11","modified_gmt":"2026-05-21T07:14:11","slug":"ss-31-elamipretide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/hu\/product\/ss-31-elamipretide\/","title":{"rendered":"SS-31 (Elamipretide)"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is SS-31 (Elamipretide)?<\/h3>\n

SS-31<\/strong> (also called Elamipretide<\/strong> vagy Bendavia<\/strong>) is a synthetic tetrapeptide that selectively binds cardiolipin<\/strong> on the inner mitochondrial membrane, stabilizing mitochondrial function under stress. Developed by the Szeto-Schiller lab and now in late-stage clinical development by Stealth BioTherapeutics with FDA orphan-drug designation for rare mitochondrial disease. Supplied in 5\u00a0mg to 50\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

Mit kapsz a MedsBase-n\u00e1l:<\/strong> Kutat\u00e1si min\u0151s\u00e9g\u0171 liofiliz\u00e1lt peptidok \u00b7 HPLC \u226599% tisztas\u00e1g (tan\u00fas\u00edtv\u00e1ny k\u00e9r\u00e9sre) \u00b7 Diszkr\u00e9t, h\u0151m\u00e9rs\u00e9klet-stabil csomagol\u00e1s \u00b7 Vil\u00e1gszerte peptid fut\u00e1rszolg\u00e1lat \u00b7 1,400+ hiteles\u00edtett v\u00e1s\u00e1rl\u00f3i v\u00e9lem\u00e9ny<\/a><\/div>\n

\ud83d\udce6 Minden rendel\u00e9st fedez a \u00dajrak\u00fcld\u00e9si Garancia<\/strong><\/a> \u2014 ha a csomagod nem \u00e9rkezik meg 20 munkanapon bel\u00fcl, \u00fajrak\u00fcldj\u00fck.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specifik\u00e1ci\u00f3<\/th>\nR\u00e9szlet<\/th>\n<\/tr>\n<\/thead>\n
CAS sz\u00e1m<\/strong><\/td>\n736992-21-5<\/td>\n<\/tr>\n
Molekul\u00e1ris k\u00e9plet<\/strong><\/td>\nC32<\/sub>H49<\/sub>N9<\/sub>O5<\/sub><\/td>\n<\/tr>\n
Molekulat\u00f6meg<\/strong><\/td>\n639.80 Da<\/td>\n<\/tr>\n
Szekvencia<\/strong><\/td>\nD-Arg-2\u2032,6\u2032-Dmt-Lys-Phe-NH2<\/sub> (Bendavia, MTP-131)<\/td>\n<\/tr>\n
Forma<\/strong><\/td>\nLiofiliz\u00e1lt por (vagy a sz\u00e1ll\u00edtott form\u00e1ban)<\/td>\n<\/tr>\n
Tisztas\u00e1g<\/strong><\/td>\n\u226599% (HPLC-vel ellen\u0151rizve, COA ig\u00e9ny szerint)<\/td>\n<\/tr>\n
T\u00e1rol\u00e1s<\/strong><\/td>\nLiofiliz\u00e1lt: 2\u20138 \u00b0C (h\u0171t\u0151szekr\u00e9ny) munkak\u00e9szletk\u00e9nt; \u221220 \u00b0C hossz\u00fa t\u00e1v\u00fa t\u00e1rol\u00e1sra lez\u00e1ratlan \u00fcvegek eset\u00e9n. Rekonstitu\u00e1lt: 2\u20138 \u00b0C, haszn\u00e1lat ~30 napon bel\u00fcl. V\u00e9dj\u00fck a f\u00e9nyt\u0151l. Ne fagyassza-v\u00e1lassza fel az \u00fajra\u00e1ll\u00edtott oldatot.<\/td>\n<\/tr>\n
Oldhat\u00f3s\u00e1g<\/strong><\/td>\nBakt\u00e9riumstatikus v\u00edz (aj\u00e1nlott) vagy steril v\u00edz r\u00f6videbb haszn\u00e1latra<\/td>\n<\/tr>\n
Kutat\u00e1si c\u00e9lra<\/strong><\/td>\nCsak laborat\u00f3riumi kutat\u00e1si c\u00e9lra. Nem haszn\u00e1lhat\u00f3 hum\u00e1n vagy \u00e1llatgy\u00f3gy\u00e1szati diagnosztikai vagy ter\u00e1pi\u00e1s c\u00e9lra.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is SS-31 (Elamipretide)?<\/h2>\n

SS-31<\/strong> is a synthetic cell-permeable tetrapeptide (D-Arg-2’6′-dimethyl-L-Tyr-L-Lys-L-Phe, also abbreviated Szeto-Schiller 31<\/strong>) developed by Hazel Szeto and Peter Schiller at Cornell’s Weill Medical College starting in the 1990s. It is also known by its pharmaceutical-development names Elamipretide<\/strong> \u00e9s Bendavia<\/strong>, and is being developed clinically by Stealth BioTherapeutics<\/strong>.<\/p>\n

Unlike most research peptides that bind cell-surface receptors, SS-31 is a mitochondria-targeted agent<\/strong> that crosses cell and organelle membranes to reach the inner mitochondrial membrane, where it binds cardiolipin<\/strong> \u2014 a phospholipid unique to that location. This selective lipid binding underpins its mechanism of action and distinguishes SS-31 from virtually every other research peptide.<\/p>\n

Molecular weight approximately 640\u00a0Da. SS-31 has FDA orphan-drug designation<\/strong> for primary mitochondrial myopathy and has been the subject of multiple human clinical trials \u2014 placing it further along the clinical development pipeline than most research peptides. It is supplied here as a high-purity lyophilized powder laborat\u00f3riumi kutat\u00e1si c\u00e9lra szolg\u00e1l<\/strong> (Stealth’s clinical product is a separate regulated therapeutic). For deeper mechanism, Szeto lab research history, and clinical-trial context, see our SS-31 research guide<\/a>.<\/p>\n

Mechanism of Action \u2014 Cardiolipin-Targeted Mitochondrial Stabilization<\/h2>\n

SS-31’s mechanism is unique among research peptides because its target is a phospholipid, not a receptor protein. Three interconnected effects define its pharmacology:<\/p>\n